Elias Jabbour, MD; Harry Paul Erba, MD, PhD; Anjali Advani, MD; and Sameem Abedin, MD, discuss key updates pertaining to the leukemia treatment landscape that were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
Estimated 3-year disease-free survival and overall survival rates topped 80% in elderly patients with Philadelphia-chromosome-positive ALL not amenable to chemotherapy.